Breast Cancer
Conditions
Brief summary
Recently, the investigators face on the edges for treatment decision to decide adjuvant systemic treatment, especially for patients who show discordance between stage and tumor biology. The aim of this study was to compare the prognostic relevance of the TNM staging system and intrinsic subtype in breast cancer patients who received curative surgery.
Detailed description
Identified patients who received curative surgery for stage I-III breast cancer and had available data on immunohistochemistry profiles including hormone receptor status (HR) status, human epidermal growth factor receptor 2 (HER2) status, and Ki 67 staining at Samsung Medical Center from January 2004 to September 2008. Primary outcomes were recurrence-free survival (RFS) and overall survival (OS).
Interventions
None listed
Sponsors
Samsung Medical Center
Study design
Observational model
OTHER
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* patients who received curative surgery * stage I-III breast cancer * between January 2004 and September 2008 * had available immunohistochemistry profiles.
Exclusion criteria
* age \<18 years old * microinvasive carcinoma of breast
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Overall survival | 1 year | was measured from the first date of diagnosis of breast cancer to the date of death or the last follow-up visit |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Recurrence-free survival | 1 Year | was defined as the time from the date of curative resection to the date when breast cancer recurred, irrespective of locoregional recurrences including ipsilateral and contralateral breast recurrences or distant metastases. |
Countries
South Korea
Contacts
Primary ContactYoung-Hyuck Im, MD, PhD
Outcome results
None listed